Global Quality Operations

Slides:



Advertisements
Similar presentations
FDA/Industry Statistics Workshop Washington D.C. September 27-29, 2006
Advertisements

Why does PAT need Rapid Microbiology Methods? S.Lonardi, P.J.Newby, D.Ribeiro, B.Johnson PAT Subcommittee meeting October 23, 2002.
National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report.
Finished Pharmaceutical Product Specifications
1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Chemistry, Manufacturing, and Controls (CMC) and Good Manufacturing Practices (GMPs): The Big Picture of a Long-term Commitment Elizabeth Pollina Cormier,
Quality by Design (QbD) in Product Development
Process Analytical Technologies Subcommittee Product and Process Development: An Industry Perspective David Rudd PhD Process Technology GlaxoSmithKline.
Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.
Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
By: Muhammad Naeem Quality Assurance and Regulatory Manager
Ray Scherzer FDA ACPS October 26, 2005 Breaking with Tradition: The Manufacturing Challenges Ahead!
Challenges and Opportunities in Enhancement of the CMC Section of NDAs: Quality – by - Design Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
Final Report on Process Analytical Technology (PAT) and Manufacturing Science Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science,
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Application of the principles of QbD in vaccines production Andrea Pranti.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Organizational Gaps in Reaching the “Desired State” Helen Winkle.
Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Overview and Objectives Ajaz S. Hussain,
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Preliminary Design Space 1.
FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration April.
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
Introduction to Topic #1: QbD approach for quality control and assurance of Dissolution Rate Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical.
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
1 An Update on ICH Guideline Q8 – Pharmaceutical Development FDA Advisory Committee for Pharmaceutical Science: 5 Oct 2006 Dr John C Berridge Senior Regulatory.
Challenges and Opportunities in Enhancement of the CMC Section of NDAs: Quality – by - Design Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
1 Basis of the Proposed Tactical Plan for a QbD approach for Quality Control and Assurance of Dissolution Rate Ajaz S. Hussain, Ph.D. Deputy Director,
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
Molecule-to-Market-Place Quality
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
10:00 A.M. – Noon 7 June 2004 ICH Quality Plenary Meeting.
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.
CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.
Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.
FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.
Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
Product & Process Working Group February 26, 2002.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
© G.K.Raju, Ph.D. Manufacturing Science Sept 17th 2003 QUALITY BY DESIGN: The Means To Fundamental Manufacturing Science G.K.Raju, Ph.D.
PROCESS ANALYTICAL TECHNOLOGY – A REVIEW By Mr. Akash Mali DEPARTMENT OF PHARMACEUTICS, G.I.P.E.R., LIMB, SATARA. 1.
An Update on ICH Guideline – Pharmaceutical Development
Quality System.
QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Quality by Design.
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
Presentation transcript:

Global Quality Operations Process Analytical Technology: Neue Trends in der Pharmaceutischen Industrie Dr. Fritz Erni NOVARTIS Pharma Global Quality Operations CH-4002 Basel, Switzerland

Outline The Vision of the desired state What is PAT and QbD ICH Q8 is a Door Opener for Describing Quality by Design Including more Science and Risk Management Introduces the Concept of Design Space Design Space Concept for Analytical Methods Summary Fritz Erni

Rising Global Regulatory Bar Global Challenges Rising Global Regulatory Bar Consent decrees and enormous fines from manufacturing compliance deficiencies Higher safety hurdles for marketing approval Challenge of Sustaining Product Pipeline & Flow Biotech contribution less than expected Government price control Challenge of Earning Stakeholders Trust Fritz Erni

What is the Problem with Pharma? Is there a Problem with Pharma? Fritz Erni

“A Paradigm in Crisis” (CAMP, R. Scherzer. FDA Sci. Board. 4/9/02) Quality by Design: A Challenge to the Pharma Industry (CAMP, R. Scherzer. FDA Sci. Board. 4/9/02) Fritz Erni

PAT in the Wall Street Journal Europe 3.9.03 FDA Commissioner Mark McClellan : ... You need to improve! ... has room for improvements: Semiconductor industry 1 ppm defects Pharmaceutical industry 5 to 10% .. Acknowledging the FDA role in inhibiting changes ... WSJE on the Lauch of the FDA PAT guideline: Fritz Erni

Impact Process Capability 2 σ 3 σ 4 σ 5 σ 6 σ Rejected Batches 31.9 % 6.7 % 0.7 % 1 %o 10 ppm Fritz Erni

Process Understanding Pharma Air Plane Fritz Erni

Typical Ingredients of a Tablet Lactose 100µm Active 5µm Corn Starch 30µm Microcrystalline Cellulose 102 100µm Fritz Erni Dr. Susanne Keitel

Where to Go? Internal and external Pressures Cost More consistent Quality No rejects/ First Time Right What will be GMP 21st Century What is the Desired State More Science Risk Management ICH Q8 / Q9 / Q10 Fritz Erni

Industry’s Vision to be achieved in 2-5 years A single global harmonized: Drug Quality Standard Interpretation of the Drug Quality Standard A Drug Quality Standard based on: Risk Management Science Mutual recognition of: “equivalent” quality system evaluations CMC review and approval Across all 3 regions. Brussels July 2003 Fritz Erni

Desired State Product quality and performance achieved and assured by design of effective and efficient manufacturing processes Product specifications based on mechanistic understanding of how formulation and process factors impact product performance An ability to effect Continuous Improvement and Continuous "real time" assurance of quality Fritz Erni

2004 2005 2006 ICH GMP and Regulatory Actions FDA PAT guideline FDA Pharmaceutical cGMP for the 21st Century – a Risk based Approach FDA PAT guideline 2004 2005 2006 FDA : Innovation and Continuous Improvement in Pharmaceutical Manufacturing FDA Draft Quality Systems Q10 Pharmaceutical Quality System Q8 Pharmaceutical Development ICH Update Q6A/B ? Q9 Risk Management Fritz Erni

‘science and risk based compliance’ The Paradigm Change From ‘blind compliance’ to ‘science and risk based compliance’ Ajaz Hussain, FDA Fritz Erni

Process Understanding Key in the Future of Manufacturing

What? Process Understanding Intended Use 1st Principles Modeling Optimization Continuous Improvement CAPA Risk based Regulatory Assessment DISCIPLINE Epidemiology Pharm. Engg. Clinical Clin.Pharm Pharm/Tox Pharmaceutics Chemistry Biology ORGANIZATION Marketing Information Technology Quality Assurance Manufacturing Regulatory Development Discovery TIME TIACC Generic AER/Complaints. Approval Phase III Phase II Phase I Fritz Erni Ajaz S. Hussain

A Process is well understood when… all critical sources of variability are identified and explained; variability is managed by the process; and, product quality attributes can be accurately and reliably predicted over the design space … http://www.fda.gov/cder/guidance/6419fnl.htm The PAT Guidance Fritz Erni

Challenges to ‘Understanding’ Understanding involves Measurements Plan Evaluate Measure Fritz Erni

Challenges to Analytical Science The need for increased Process understanding is a massive Boost for Analytical Science Fritz Erni

Challenges to Analytical Science adequate Tools? Fritz Erni

Challenges to Analytical Science adequate Tools ! Fritz Erni

Challenges to Analytical Science We need the adequate Tools Fritz Erni

PAT: Process Understanding Improved Process Knowledge to Identify and Remove Sources of Variability Identify Critical to Quality parameters Process understanding as input to Risk Management Control what is critical Fritz Erni

What is Quality by Design Elements of a QbD Systematic Development Approach Formulation Understanding Process Understanding Packaging Understanding Application of Quality Risk Management Advanced Control Strategy Fritz Erni

Quality by Design Conventional PD Quality by Design(ideal) Mainly empirical approach A systematic approach Quality assured by end-product testing and inspection Quality assured by well understood product and process, moving controls upstream without relying on end-product testing as much as possible Process is fixed, disallowing changes Flexible process within design space, allowing continuous improvement Focus on process reproducibility – often avoiding or ignoring variability Focus on formulation and process robustness – understanding and controlling variability Limited and simple IPC Extended PAT tools replacing the need for end product testing Fritz Erni

ICH Q8 Door opener for Quality by Design What is ICH Q8 Guideline for the description what is in P2 Describes the minimal Standard for P2 Opens door to get closer to the ‘Desired State’ Science based Includes Risk Management Continuous improvement Real Time Release ICH Q8 Door opener for Quality by Design Fritz Erni

Design Space The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality. Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory post approval change process. Design space is proposed by the applicant and is subject to regulatory assessment and approval. Fritz Erni

Design Space Is Key for claiming Process Understanding Process understanding is Key for Quality Risk Management QRM is the base for any Control Strategy

Design of Experiments (DoE) Effect of inlet temperature and air flow on degradation and generation of fines Fritz Erni

Examplain Design Space – Graphical Description Figure 33 (p.41/54) "Graphical description of the design space for the drying operation for examplain hydrochloride tablet manufacture" Fritz Erni

Quality Risk Management Q9 and the Control Strategy Fritz Erni

The Quality Risk Management Process Fritz Erni

Cause and Effect Process Fritz Erni

QRM Tools: Failure Mode Effects Analysis (FMEA) Fritz Erni

Risk Management process Unit operation Granulation Drying Blending Tableting Dispensation Quality Attributes Dissolution Disintegration Hardness Assay Content Uniformity Degradation Stability Appearance Identification Water Microbiology Significant influence Initial assessment Prior knowledge First & Second review cycle Formulation and Process understanding Third review cycle Control Strategy Fritz Erni

Control Strategy Justification of necessary controls Raw Materials Control In-Process Controls End Product Controls (if necessary) Based on Process and Formulation Understanding Drives the Process in the Design Space Based on Quality Risk Management To ensure conforming Quality according Specifications Fritz Erni

Blend Homogeneity -NIR Extent of Wet Massing - Power Consumption Control Strategy Unit Operations Attributes Controls Content Uniformity NIR Water Content – NIR Particle size – FBRM Dispensation Blending Fluidized Bed Dryer Packaging Tableting Identity-NIR Blend Homogeneity -NIR Granulation Extent of Wet Massing - Power Consumption Air Scale Multivariate Model (predicts Disintegration) Raw Materials Fritz Erni

Can the design space concept also be applied to Q8 Design Space Can the design space concept also be applied to Analytical Methods? Fritz Erni

What is Analytical Method Understanding? Q8 Design Space What is Analytical Method Understanding? Fritz Erni

Dr.Imre Molnar,Institut für angewandte Chromatography,Berlin, Germany

Rising Global Regulatory Bar Global Challenges Rising Global Regulatory Bar Consent decrees and enormous fines from manufacturing compliance deficiencies Higher safety hurdles for marketing approval Industry’s pain for post approval changes Biotech contribution less than expected Government price control Challenge of Earning Stakeholders Trust Fritz Erni

Industry’s pain for post approval changes Many are method changes Most of the changes are urgent Many of them are improvements US FDA has recognized the issue Moheb Nasr (FDA) offers working together with industry Industry needs to show interest and takes it up Fritz Erni

Design Space of a Separation Method What do we need to understand? What does Industry need as flexibility Separation parameters fixed or with ranges Separation parameters as a design space Variability of HPLC columns included How is understanding related to the flexibility How to put it in a dossier How is it reviewed and approved Fritz Erni

Design Space of a Separation Method The role of Method development Method validation System suitability How to describe the enhanced understanding How to describe the design space How to update the analytical design space What is the ‘regulatory flexibility’ Fritz Erni

Summary The Vision of the desired state What is PAT and QbD ICH Q8 is a Door Opener for Describing Quality by Design Including more Science and Risk Management Introduces the Concept of Design Space Design Space Concept for Analytical Methods Fritz Erni

Alles zu messen was messbar ist - Und messbar machen was noch nicht messbar ist! Galileo Galilei 1564-1642 Fritz Erni